Case Overview

FeganScott launched an investigation into Sanofi, the makers of Zantac, the popular over-the-counter medication for the treatment of heartburn, and its generic and over-the-counter equivalents. Studies detected NDMA, a possible human carcinogen, in ranitidine, the generic compound used in Zantac. Following these results, the brand name and generic drug makers issued a recall—noting the associated health risks. As advocates for consumer safety, we have launched an investigation into Zantac to protect those who may have been exposed to NDA over a long period of time.

If you have taken Zantac 150, Zantac 150 Cool Mint or Zantac 75 for more than five years and care concerned about your risk of developing cancer, please contact us at zantac@feganscott.com to join our investigation.